Association of various myositis-specific autoantibodies with dermatomyositis and polymyositis triggered by pregnancy
- PMID: 33837447
- DOI: 10.1007/s00296-021-04851-1
Association of various myositis-specific autoantibodies with dermatomyositis and polymyositis triggered by pregnancy
Abstract
Although pregnancy is an important risk factor for autoimmune rheumatic diseases, little is known regarding the association between pregnancy and dermatomyositis (DM) or polymyositis (PM). Herein, we present two patients with DM that developed during the perinatal period. The first patient was positive for anti-aminoacyl synthetase (ARS) antibody and developed DM in the 14th week of pregnancy. Despite treatment, her foetus died of intrauterine growth restriction in the 27th week. The second patient was positive for anti-melanoma differentiation-associated gene 5 (MDA-5) antibody and developed DM 1 week after miscarriage at 9 weeks of gestation. The patient developed severe interstitial pneumonia, and intensive therapy including tofacitinib and rituximab administration was required. Our cases and a literature review revealed that various myositis-specific autoantibodies, including anti-ARS, anti-Mi-2, anti-TIF-1γ, and anti-MDA-5, are associated with DM and PM triggered by pregnancy. We also found that delay in commencing treatment in case of active disease including myositis and interstitial pneumonia, and poor response to corticosteroids were related to poor foetal outcomes in DM and PM. Although rare in pregnant women, it is critical to consider the possibility of DM and PM in patients presenting with rash, fever, weakness, and cough, and testing for myositis-specific autoantibodies is recommended.
Keywords: Dermatomyositis; Myositis-specific autoantibodies; Polymyositis; Pregnancy.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Giles I, Yee CS, Gordon C (2019) Stratifying management of rheumatic disease for pregnancy and breastfeeding. Nat Rev Rheumatol 15:391–402. https://doi.org/10.1038/s41584-019-0240-8 - DOI - PubMed
-
- Oya K, Inoue S, Saito A, Nakamura Y, Ishitsuka Y, Fujisawa Y, Watanabe R, Taguchi S, Fujimoto M, Okiyama N (2020) Pregnancy triggers the onset of anti-transcriptional intermediary factor 1gamma antibody-positive dermatomyositis: a case series. Rheumatology (Oxford) 59:1450–1451. https://doi.org/10.1093/rheumatology/kez527 - DOI
-
- Machiyama T, Shirai T, Fujita Y, Sato H, Fujii H, Ishii T, Harigae H (2021) Successful concomitant therapy with tofacitinib for anti- melanoma differentiation associated gene 5 antibody-positive rapidly progressive interstitial lung disease with poor prognostic factors. Med Case Rep Study Protoc 2:e0026. https://doi.org/10.1097/MD9.0000000000000026 - DOI
-
- Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417. https://doi.org/10.1007/s00296-011-1999-3 - DOI - PubMed
-
- Papapetropoulos T, Kanellakopoulou N, Tsibri E, Paschalis C (1998) Polymyositis and pregnancy: report of a case with three pregnancies. J Neurol Neurosurg Psychiatry 64:406. https://doi.org/10.1136/jnnp.64.3.406 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
